Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

Bayer (BAYGn.DE), opens new tab will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in ...

( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 20, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering.

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

2025 Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an interview ...

Durham-based Tavros Therapeutics, a precision oncology company spun out of Duke University, has been acquired by a subsidiary of global life sciences titan Bayer AG. Financial terms of the deal with ...

Bernstein analyst Florent Cespedes maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €30.00. The ...

(Bloomberg) -- Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the company still faces after its $63 billion acquisition of ...